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istic of an addiction. Relapse following addiction treatment is very common with serious consequences to
individuals, families, and the public system of care, making predictors of relapse a highly significant area
of study. Before the turn of the century, most of the addiction treatment outcome literature focused on
psychosocial predictors of relapse. More recently, investigating biological predictors of relapse specifi-
cally and treatment outcome broadly has gained momentum. This line of research has linked sleep dis-
turbances to the risk of relapse among persons who are recovering from an alcohol addiction. Given
common neurobiological and psychosocial processes in sleep and addictive behaviors, we hypothesize
that the link between sleep disturbance and relapse risk observed among alcohol addiction generalizes
to all other types of psychoactive substances. This hypothesis has the potential for helping develop more
effective and targeted treatment approaches for persons with addiction. As initial support for the hypoth-
esis, this paper reviews evidence on common neurobiological processes among various types of psycho-
active substances that suggests sleep is a universal risk factor for relapse. A conceptual framework is also
presented to articulate causal mechanisms. The paper concludes with implications for research and
practice.
 2009 Elsevier Ltd. All rights reserved.Introduction
Relapse to uncontrolled use of a psychoactive substance is argu-
ably the single most defining characteristic of an addiction, a
source of immense frustration that is accompanied by tragic conse-
quences for patients and society, and a primary target for addiction
treatment research. Unfortunately, relapse following addiction
treatment is very common and, therefore, predictors of relapse
are a highly significant area of study. Before the turn of the century,
most of the addiction treatment outcome literature focused on
psychosocial predictors of relapse, which includes the long list of
variables in Table 1. The underlying premise for studying these
variables is that some might be modifiable, such as increasing
self-efficacy, while other variables might respond optimally to spe-
cifically targeted treatment programs (e.g., gender, age).
More recently, investigating biological predictors of treatment
outcome has gained momentum. Human studies in this area have
shown relationships between relapse and (a) genetic variants [1–
5], (b) size of specific brain structures [6], (c) functioning of various
neurotransmitters and neuroendocrine systems [7–17], (d)
activation of specific neuroanatomical regions as measured with
functional brain imaging [18–20], and (e) patterns of electrophys-ll rights reserved.
: +1 734 998 7992.
.
iological brain patterns [21–26], including neurophysiological cor-
relates of sleep [27–29]. The investigation of biological predictors—
which for the most part are neurobiological predictors—is consis-
tent with the currently dominant paradigm in addiction research,
namely that addiction is a brain disease. According to this para-
digm, if we can delineate how the brain is altered in affected indi-
viduals, then we can improve upon treatment strategies by
targeting these specific neurobiological alterations, for example,
with pharmacotherapy agents. Not surprisingly for a dominant
paradigm, a proliferation of scholarly reviews of the neurobiology
of addiction has recently been published [30–33].
Of course, most experts would agree that addiction is not sim-
ply a brain disease, but rather a disorder that is strongly influenced
by psychological, social, and cultural factors in addition to genetic,
epigenetic, and neurobiological ones. While agreeing to the
importance of non-biological factors in the etiology and course of
substance use disorders, we will focus on a biological one, specifi-
cally sleep, which is also influenced strongly by psychosocial and
cultural factors. Sleep disturbance offers a number of advantages
when investigating predictors of addiction treatment outcome.
For example, it is a common symptom across all substance-related
withdrawal disorders recognized in the DSM-IV [34]. Psychological
and pharmacological treatments are available to address sleep
disturbances among persons with substance-related disorders
[35,36]. Thus, with proper assessment and targeted sleep-related
Table 1
Psychosocial predictors of relapse to substance dependence.
Demographics
Severity of dependence
Age at onset of problem use
Family history of substance use disorders
Co-occurring mental and other substance use disorders
Psychiatric severity




Length of treatment stay
Participation in Alcoholics Anonymous or similar mutual-help groups
Therapeutic alliance
Self-efficacy
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successful outcomes for this at-risk population. Finally, systematic
investigation of the relationship between sleep disturbance and re-
lapse can advance our knowledge on the basic science of addiction
and treatments.Hypothesis
Current research suggests that sleep disturbances among per-
sons who are recovering from an alcohol addiction and have a
sleep disturbance are at an elevated risk of relapse compared to
those without a sleep disturbance. Given common neurobiological
and psychosocial processes in sleep and addictive behaviors, we
believe this sleep-related relapse risk for alcohol generalizes to
all other types of psychoactive substances. In formalized terms,
we hypothesize that persons who are recovering from an addiction
to any psychoactive substance and have a sleep disturbance are at
an increased risk of relapse compared to those without a sleep dis-
turbance. In other words, sleep disturbance is a universal risk factor
for relapse in addiction to all psychoactive substance. For this
hypothesis, a sleep disturbance refers to any problems involved
with falling asleep, staying asleep, distressing dreams, or inability
to progress through normal stages of sleep.
We describe this hypothesis by first presenting research that
shows an association between sleep disturbance and relapse
among persons with an alcohol addiction. This is followed by a re-
view of other research highlighting common neurobiological fac-
tors that provides a foundation for generalizing this association
to other psychoactive substances. We then present sleep distur-
bance as a universal risk factor for relapse within a conceptual
framework to describe the underlying causal mechanisms for this
universal risk factor in relapse. We conclude with research and
treatment implications based on the hypothesis.Evidence that sleep predicts relapse across psychoactive
substances
Alcohol
The largest body of evidence relating sleep disturbance to re-
lapse involves studies of alcohol dependence, for which both sub-
jective and objective measures of sleep at baseline have predicted
subsequent relapse [27,37]. A 2003 review of the literature cited 12
publications from 1975 to 2001 by six different research groups
demonstrating a relationship between sleep disturbance and re-
lapse [38]. Since that time, at least three other reports have ap-
peared which extend the evidence [39–41]. In general, the
literature indicates that increased sleep latency and its subjective
correlate (trouble falling asleep) as well as significantly more rapideye movement (REM) sleep or ‘‘REM pressure” are replicated pre-
dictors of alcoholic relapse. Not included in this review is a 1973
publication citing dreams of alcohol-dependent patients as a prog-
nostic factor [42]. Since then, another data-based publication
describing polydrug users, including alcohol abusers, was consis-
tent with this early observation [43]. Finally, a more recent report
describing a series of cases stressed the importance of paying treat-
ment attention to so-called ‘‘using” dreams in order to prevent re-
lapse [44].
Cocaine and amphetamines
Although the literature on addiction-related dreaming and re-
lapse is less substantial than for other sleep parameters, there
are three reasons to take the phenomenon seriously. First is the
inclusion of unpleasant, vivid dreams as a criterion symptom for
both amphetamine and cocaine withdrawal [34]. Second, Sofuoglu
and colleagues [45] reported from a cross-sectional survey that vi-
vid, unpleasant dreams during cocaine withdrawal were associated
with a history of addiction treatment, severe depression, and trad-
ing sex for cocaine or cocaine for sex; i.e., a more severe course of
the disorder. Third is the association of rapid eye movement (REM)
sleep pressure—a correlate of dream sleep—and relapse to alcohol
dependence that has been independently documented by two dif-
ferent research groups [29,46].
Nicotine
At least three recent studies are suggestive that events during
the sleep period predicted relapse to smoking tobacco [47–49].
One of these reported that awakening during the night as mea-
sured by a nicotine withdrawal scale was negatively associated
with abstinence for 6 months after starting treatment [47]. An-
other found that participants who had a history of smoking during
their sleep period (after going to bed but before their final awaken-
ing in the morning) had an earlier time to their first smoking epi-
sode within 4 weeks of their quit date [49]. None of these studies
employed polysomnography.
Opioids
We were unable to find evidence that poor sleep predicted re-
lapse in patients dependent on opioids. Paradoxically, one recent
study reported that poor sleep during opioid detoxification was
associated with abstinence during a 4-week follow-up period
[50]. The authors speculated that treatment staff may have given
more attention to poor sleepers, resulting in better outcomes, but
they could not support that explanation with data. Again, polysom-
nography was not performed.
Sedative-hypnotics
Regarding sedative-hypnotic dependence, there is general con-
sensus that sleep disturbances perpetuate the disorder [51–54],
but this relationship has not been formally tested.
Conceptual framework for the sleep disturbance-relapse
hypothesis
The evidence that sleep disturbance is linked to relapse is stron-
gest for alcohol dependence. Two sets of arguments for generaliz-
ing the link between sleep disturbance and relapse to other
psychoactive substances are provided below. The first of these
arguments is based on the commonality of sleep disturbances
across psychoactive substances, while the second of these sections
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dictor of treatment outcome.
Commonality of sleep disturbance
The phenomenology and course of acute withdrawal following
a reduction in or discontinuation of dependent substance use is
well-described diagnostically for six classes of substances, namely
alcohol, amphetamines, cocaine, nicotine, opioids, and sedative-
hypnotics [34]. An examination of the diagnostic criteria across
this list of substances reveals that sleep disturbances are the only
group of symptoms that all withdrawal disorders share in common
(refer to DSM-IV). Insomnia per se is listed across all substance
withdrawal disorders, although sleep disturbance for some sub-
stances (cocaine and amphetamines) also includes hypersomnia
or unpleasant, vivid dreams. Accordingly, we define insomnia as
a universal withdrawal symptom, meaning that it occurs across all
DSM-IV diagnoses of substance withdrawal. Likewise, if anxiety
and depressed mood are combined to represent negative affect,
then they form another group of universal withdrawal symptoms
[55].
Depending on the class of substance and its elimination phar-
macokinetics, acute withdrawal generally lasts 1 week or less,
and sometimes for 3–4 weeks with longer-acting drugs. Other
symptoms and their neurophysiological correlates have been
shown to persist after acute withdrawal has abated in both hu-
mans and animal models [56]. These persistent symptoms, which
include insomnia and negative affect, have been variously labeled
as protracted withdrawal [56,57] or subacute withdrawal symp-
toms [58]. Protracted or subacute withdrawal can be defined as a
constellation of symptoms and neurobiological alterations that
(a) persist beyond the time-course of acute substance withdrawal
and (b) increase the risk for relapse. The notion of protracted or
subacute withdrawal implies that its symptoms begin during acute
withdrawal and persist. Some symptoms, however, including
insomnia and negative affect may begin prior to the development
of substance dependence [59] and continue to persist during pro-
tracted abstinence. Therefore, we prefer the term protracted absti-
nence symptoms [60], because it is descriptive of symptoms that
are evident after the period of acute withdrawal without making
any assumptions about chronology. (Nevertheless, the clinical
implications of such chronological differences in symptom onset
are worthy of further study.) A third class of symptoms, although
not included in DSM-IV criteria for any substance withdrawal dis-
orders, consists of craving or urges to use, which may also be a can-
didate for a universal symptom of protracted abstinence.
The conceptual framework of universal protracted abstinence
symptoms proposes that clinical symptoms (such as sleep distur-
bances, negative affect, and craving) are manifestations of underly-
ing neurobiological abnormalities, which are common to
addictions across drugs of abuse.
Sleep disturbance as a predictor of treatment outcome
Several properties of sleep disturbance suggest that investigat-
ing their role in addiction may be particularly advantageous in fur-
thering our knowledge about predicting treatment outcome. While
there are numerous advantages to be considered, we focus on four
that are particularly salient to the hypothesis presented.
First, as discussed above, sleep disturbances occur commonly
with use and withdrawal across a number of addictive sub-
stances. This literature has recently been reviewed for dependent
users of alcohol [61], cannabis [62,63], cocaine [62,64,65], nico-
tine [66], opioids [67], and hallucinogens such as MDMA
[62,68]. In addition, sedative-hypnotics drugs, which are a main-
stay of insomnia treatment worldwide, are associated with abuseand dependence, and ongoing sleep disturbance is common
among individuals that either abuse or become dependent on
sedative-hypnotics [51–54].
Second, unlike the other proposed universal protracted absti-
nence symptoms (craving and negative affect), sleep is the only
one that can directly be studied objectively, whereas craving and
negative affect cannot be studied without relying on subjective
self-report of the experience. While neurophysiological correlates
of self-reported craving [69–71] and negative affect [72] in ad-
dicted individuals can be studied, one really only knows that peo-
ple are having these experiences if they say they are. By contrast,
sleep is defined neurophysiologically as measured by polysomnog-
raphy. Thus, it is known and measurable when people are asleep
without them having to say so. Nevertheless, sleep can also be
studied by correlating neurophysiological measures with subjec-
tive reports. When this is done, important discrepancies between
self-reported and objectively measured sleep become apparent to
sleep researchers and clinicians [73]. Individuals commonly under-
estimate or overestimate how much time they spent sleeping and
awake during the night, as well as how long it took them to fall
asleep. Moreover, such discrepancies have recently been reported
in alcohol-dependent individuals [39,74]. By inference, therefore,
correlations between neurophysiological measures and either
self-reported craving or negative affect are likely subject to similar
discrepancies. With sleep, however, polysomnography represents
the gold standard of measurement, whereas no such gold standard
exists for craving or negative affect.
Third, sleep is an unconscious activity. With the possible excep-
tion of lucid dreaming [75], what happens during sleep is not un-
der our conscious control. Likewise, much of what happens
during addiction is not under the conscious control of its sufferers.
From a diagnostic perspective, loss of control or impaired control
over use of a substance has long been recognized as the sine qua
non of addiction. Puzzling to both addicted individuals and those
who observe them, they ingest substances recurrently despite
every conscious reason and desire not to. From a neurobiological
perspective, such puzzling behavior has been attributed to altera-
tions in subcortical and limbic system activity that operate outside
a conscious level. Therefore, sleep offers a window into the activity
of the brain in its unconscious state, which may potentially provide
clues about the unconscious brain activity that underlies and
drives addiction [30–33].
Finally, addiction researchers have prolific allies in the study of
sleep. Sleep medicine is a recognized specialty that is informed by
an extensive base of scientific evidence, much of which is pub-
lished in at least 11 English-language sleep-specific journals [76].
In addition, both basic and clinical research are generating new
knowledge about the neurobiology [77–79] and genetics [80] of
sleep, some of which has particular relevance for the study of
addictions [81,82]. Therefore, ongoing research activity regarding
the effects of several different drugs of abuse on sleep is of interest
to both sleep and addiction researchers [59,83–92].Implications
Research
Despite over 30 years of evidence that addiction-related sleep
disturbances are predictors of relapse, this area of research is still
in its infancy. While details of a comprehensive research agenda
are beyond the scope of this article, a few next steps for studying
sleep as a predictor of relapse are offered. As discussed above,
the current evidence for linking sleep and relapse is strongest for
alcohol dependence, because it is the best studied. Additional stud-
ies on the potential relationship between sleep disturbances and
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cocaine, nicotine, and opioids.
Sleep measures should be considered for inclusion in all ran-
domized clinical trials and naturalistic studies of treatment out-
come. Although polysomnography is the gold standard, much
information could be gained by simpler measures such as actigra-
phy, sleep logs, and self-report instruments. Unfortunately, these
measures have not been validated specifically for sleep distur-
bances that occur among patients with addiction. Validating sleep
measures in addicted populations can lead to consensus about
which ones are most useful in clinical research. Furthermore, vali-
dation studies will decrease the number of instruments currently
employed and allow for better comparability between studies.
The mechanisms for a relationship between sleep disturbance
and relapse is unknown and an area for further study. One possibil-
ity is that insomnia is linked to co-occurring psychiatric disorders
that worsen the course of substance dependence, particularly
mood disorders, anxiety disorders, and attention deficit disorder,
which all have well-described sleep disturbances. Another possi-
bility is that insomnia is an indicator of severity of dependence,
which would be expected to increase relapse rates. Third, insomnia
may be linked to impulsivity [93], which in turn is linked to relapse
[94]. Fourth, it is possible that chronic sleep deprivation from
insomnia adversely affects cerebral executive functions such as
judgment during high relapse-risk situations. Fifth, it is possible
that patients relapse to substances as an attempt to self-medicate
their sleep disturbance, which worsens during and persists after
acute withdrawal.
Even after accounting for all of these factors, which are not
mutually exclusive, we believe that addiction to substances is asso-
ciated with dysfunction in regions of the brain that regulate sleep.
In this regard, animal studies are particularly conducive for re-
search on dysfunctional brain systems, which overlap in the path-
ogenesis of both addiction and sleep disturbance.Treatment
The conventional wisdom among addiction treatment profes-
sionals is that both the pharmacological effects of drugs and the
psychosocial stressors associated with addiction disrupt sleep. This
is reasonable, except when patients are subsequently told that
their natural sleep rhythms will return to normal with abstinence
from substances and recovery from addiction. While this may be
true for some patients, it is not true for everyone. Indeed, sleep dis-
turbances can persist for months to years following initiation of
abstinence [37], if they do not result in relapse before then. There-
fore, other approaches may be indicated and have been reviewed
elsewhere [35,36]. It deserves emphasis, however, that although
insomnia may predict relapse, it is unproven that treatment of
insomnia prevents relapse. For example, one recent randomized
controlled trial of trazodone (a sedating antidepressant) vs. pla-
cebo found that alcohol-dependent participants receiving active
medication had improved sleep but drank more frequently and
heavily during the study [95]. Although the explanation for this
finding is unclear at this time, clinicians should use medication
judiciously, employ behavioral techniques whenever possible,
and monitor dependent patients with sleep disturbances closely.Summary
Measures of sleep disturbance in substance-dependent patients
are common across different drugs of abuse and persist following
the course of acute withdrawal into the period of protracted absti-
nence. Sleep disturbances are theorized to reflect neurobiological
dysfunction, increase relapse risk, and be amenable to pharmaco-therapy when the mechanisms underlying addiction and sleep dis-
turbance are better understood. Although the current evidence is
strongest for alcohol addiction, we have specifically examined
the hypothesis that persons who are recovering from an addiction
to any psychoactive substance and have a sleep disturbance are at
an increased risk of relapse compared to those without a sleep distur-
bance. Sleep disturbance can include both objectively measured
and subjectively reported problems involved with falling asleep,
staying asleep, distressing dreams, or inability to progress through
normal stages of sleep. Sleep disturbance was further described as
belonging to a group of universal withdrawal symptoms or universal
symptoms of protracted abstinence. Negative affect and craving (or
urges to use substances) are the other two members of the group.
What makes these symptoms universal is their occurrence during
withdrawal and prolonged abstinence from each of the most fre-
quently used addictive substances (alcohol, amphetamines, canna-
bis, cocaine, nicotine, opioids, and sedative-hypnotics). What
makes sleep most unique when compared to negative affect and
craving is that objective measurement (via polysomnography) is
possible, whereas the other two require subjective self-report to
define their presence. Objective measurement will allow more di-
rect correlations with other neurobiological mediators of addic-
tion. Future research will determine if hallucinogens other than
MDMA, inhalants, and phencyclidine/ketamine are also character-
ized by sleep disturbance.Conflict of interest
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